Referencias bilibiográficas
1. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoSMed 2013; 10(7): e1001484.
2. Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. Environmental determinantsof severity in sickle cell disease.Haematologica2015; 100: 1108-16.
3. Rees DC, Williams TN, Gladwin MT.Sickle-cell disease. Lancet 2010; 376: 2018-31.
4. Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell geneand geographical confirmation of the malariahypothesis. Nat Commun 2010; 1: 104.
5. Elguero E, Delicat-Loembet LM, Rougeron V, et al. Malaria continues toselect for sickle cell trait in Central Africa. ProcNatlAcadSci U S A 2015; 112: 7051-4.
6. Piel FB, Tatem AJ, Huang Z, Gupta S, Williams TN, Weatherall DJ. Global migrationand the changing distribution of sickle haemoglobin: a quantitative study oftemporal trends between 1960 and 2000.Lancet Glob Health 2014; 2(2): e80-e89.
7. Hassell KL. Population estimates ofsickle cell disease in the U.S. Am J PrevMed 2010; 38: Suppl: S512-S521.
8. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013; 381: 142-51.
9. Weatherall DJ. The inherited diseasesof hemoglobin are an emerging globalhealth burden. Blood 2010; 115: 4331-6.
10. DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med 2014; 371: 699-710.
11. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia — TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non inferiority trial. Lancet 2016; 387: 661-70.
12. Yawn BP, Buchanan GR, Afenyi-AnnanAN, et al. Management of sickle cell disease:summary of the 2014 evidencebasedreport by expert panel members.JAMA 2014; 312: 1033-48.
13. Bello-Manga H, DeBaun MR, Kassim AA. Epidemiology and treatment of relativeanemia in children with sickle celldisease in sub-Saharan Africa. Expert Rev Hematol 2016; 9: 1031-42.
14. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115: 3447-52.
15. Le PQ, Gulbis B, Dedeken L, et al. Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment. Pediatr Blood Cancer2015; 62: 1956-61.
16. Gardner K, Douiri A, Drasar E, et al. Survival in adults with sickle cell disease in a high-income setting. Blood 2016; 128:1436-8.
17. Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. Blood2014; 124: 3850-3857, quiz 4004.
18. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of healthcare for children and adults with sicklecell disease. Am J Hematol 2009; 84: 323-7.
19. Shortell SM, Addicott R, Walsh N,Ham C. The NHS Five Year Forward View:lessons from the United States in developingnew care models. BMJ 2015; 350:h2005.
20. Kyu HH, Pinho C, Wagner JA, et al. Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013: findings from the Global Burden of Disease 2013 study. JAMA Pediatr 2016; 170: 267-87.
21. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med 2011; 41: Suppl 4: S398-S405.
22. Serjeant GR. The role of preventivemedicine in sickle cell disease: the WatsonSmith lecture. J R Coll Physicians Lond 1996; 30: 37-41.
23. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 2000; 342: 1855-65.
24. Ware M, Tyghter D, Staniforth S, SerjeantG. Airline travel in sickle-cell disease.Lancet 1998; 352: 652.
25. Bitoungui VJ, Pule GD, Hanchard N, Ngogang J, Wonkam A. Beta-globin gene haplotypes among cameroonians and review of the global distribution: is there a case for a single sickle mutation origin in Africa? OMICS 2015; 19: 171-9.
26. Weatherall MW, Higgs DR, Weiss H, Weatherall DJ, Serjeant GR. Phenotype/genotype relationships in sickle cell disease: a pilot twin study. Clin Lab Amatol 2005; 27: 384-90.
27. Hofrichter J, Ross PD, Eaton WA. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci U S A 1974; 71: 4864-8.
28. Steinberg MH, Embury SH. Alpha thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood 1986; 68: 985-90.
29. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol2012; 87: 795-803.
30. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. BloodRev 2007; 21: 37-47.
31. Taylor JG VI, Nolan VG, Mendelsohn L, Kato GJ, Gladwin MT, Steinberg MH. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 2008; 3(5):e2095.
32. Cannon RO III, Schechter AN, Panza JA, et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest 2001; 108: 279-87.
33. Dejam A, Hunter CJ, Schechter AN,Gladwin MT. Emerging role of nitrite inhuman biology. Blood Cells Mol Dis 2004;32: 423-9.
34. Kim-Shapiro DB, Schechter AN, GladwinMT. Unraveling the reactions of nitricoxide, nitrite, and hemoglobin in physiologyand therapeutics. ArteriosclerThromb Vasc Biol 2006; 26: 697-705.
35. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA2005; 294: 81-90.
36. Landburg PP, Teerlink T, Biemond BJ,et al. Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. Blood Cells Mol Dis 2010; 44: 229-32.
37. Kato GJ. Defective nitric oxide metabolism in sickle cell disease. Pediatr Blood Cancer 2015; 62: 373-4.
38. Akinsheye I, Alsultan A, Solovieff N,et al. Fetal hemoglobin in sickle cell anemia.Blood 2011; 118: 19-27.
39. Nagel RL, Fabry ME, Pagnier J, et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa —the Senegal type and the Benin type. N Engl J Med 1985; 312: 880-4.
40. Masuda T, Wang X, Maeda M, et al.Transcription factors LRF and BCL11Aindependently repress expression of fetalhemoglobin. Science 2016; 351: 285-9.
41. Bae HT, Baldwin CT, Sebastiani P, et al. Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood 2012; 120: 1961-2.
42. Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 2013; 342: 253-7.
43. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A,HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A 2008; 105: 11869-74.
44. Alsultan A, Alabdulaali MK, GriffinPJ, et al. Sickle cell disease in Saudi Arabia:the phenotype in adults with the Arab-Indian haplotype is not benign. Br J Haematol 2014; 164: 597-604.
45. Perrine RP, John P, Pembrey M, PerrineS. Sickle cell disease in Saudi Arabsin early childhood. Arch Dis Child 1981;56: 187-92.
46. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs: a study of 270 subjects. Ann Intern Med 1978; 88: 1-6.
47. Dean A. On a chromosome far, faraway: LCRs and gene expression. TrendsGenet 2006; 22: 38-45.
48. Vathipadiekal V, Alsultan A, Baltrusaitis K, et al. Homozygosity for a haplotypein the HBG2-OR51B4 region is exclusive to Arab-Indian haplotype sickle cell anemia. Am J Hematol 2016; 91(6): E308-E311.
Comentarios
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.